FDA moves BPC-157 to Category 1 by…?
FDA moves BPC-157 to Category 1 by…? Live odds across 4 markets: Before 2027 at 54¢. Resolves Jan 1, 2027. Not financial advice.
Resolves Jan 1, 2027
- Before September: Yes 7¢ (polymarket)
- Before 2027: Yes 54¢ (kalshi)
- Before November: Yes 37¢ (kalshi)
- December 31, 2026: Yes 52¢ (polymarket)
FDA moves BPC-157 to Category 1 by…?
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
$80.2K
+$580 (24h)
4
Across 2 platforms
54¢
Before 2027
-35¢
December 31, 2026
0
None detected
All Markets
Implied Probability
Consensus across platformsEvent Info
Whale Activity
Loading...